Literature DB >> 16101486

Competition dialysis: an assay to measure the structural selectivity of drug-nucleic acid interactions.

Jonathan B Chaires1.   

Abstract

Competition dialysis is a powerful new tool for the discovery of ligands that bind to nucleic acids with structural- or sequence-selectivity. The method is based on firm thermodynamic principles and is simple to implement. In the competition dialysis experiment, an array of nucleic acid structures and sequences is dialyzed against a common test ligand solution. After equilibration, the amount of ligand bound to each structure or sequence is determined spectrophotometrically. Since all structures and sequences are in equilibrium with the same free ligand concentration, the amount bound is directly proportional to the ligand binding affinity. Competition dialysis thus provides a direct and quantitative measure of selectivity, and unambiguously identifies which of the structures or sequences within the sample array that are preferred by a particular ligand. Following the introduction of the method, competition dialysis has been used worldwide to probe a variety of ligand-nucleic acid interactions. This contribution will focus on new analytical approaches for extracting information from the database that resulted from the first-generation competition dialysis assay, in which binding data was gathered for the interaction of 126 compounds with 13 different structures and sequences. Such global analyses allow identification of compounds with unique types of binding selectivity.

Mesh:

Substances:

Year:  2005        PMID: 16101486     DOI: 10.2174/1568011054222292

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  18 in total

1.  Thionine interaction to DNA: comparative spectroscopic studies on double stranded versus single stranded DNA.

Authors:  Puja Paul; Gopinatha Suresh Kumar
Journal:  J Fluoresc       Date:  2011-08-10       Impact factor: 2.217

2.  Use of competition dialysis in the discovery of G-quadruplex selective ligands.

Authors:  Patricia Ragazzon; Jonathan B Chaires
Journal:  Methods       Date:  2007-12       Impact factor: 3.608

Review 3.  Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments.

Authors:  Ngolela E Babady; Nadege Carelle; Robert D Wells; Tracey A Rouault; Michio Hirano; David R Lynch; Martin B Delatycki; Robert B Wilson; Grazia Isaya; Hélène Puccio
Journal:  Mol Genet Metab       Date:  2007-06-26       Impact factor: 4.797

4.  Probing the molecular recognition of a DNA.RNA hybrid duplex.

Authors:  Richard T Wheelhouse; Nichola C Garbett; Niklaas J Buurma; Jonathan B Chaires
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-19       Impact factor: 15.336

5.  Thermodynamics of nucleic acid "shape readout" by an aminosugar.

Authors:  Hongjuan Xi; Erik Davis; Nihar Ranjan; Liang Xue; David Hyde-Volpe; Dev P Arya
Journal:  Biochemistry       Date:  2011-10-03       Impact factor: 3.162

6.  Quantitative analysis of small molecule-nucleic acid interactions with a biosensor surface and surface plasmon resonance detection.

Authors:  Yang Liu; W David Wilson
Journal:  Methods Mol Biol       Date:  2010

7.  A small molecule--DNA binding landscape.

Authors:  Jonathan B Chaires
Journal:  Biopolymers       Date:  2015-09       Impact factor: 2.505

Review 8.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

9.  Ligand binding mode to duplex and triplex DNA assessed by combining electrospray tandem mass spectrometry and molecular modeling.

Authors:  Frédéric Rosu; Chi-Hung Nguyen; Edwin De Pauw; Valérie Gabelica
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-28       Impact factor: 3.109

Review 10.  Structure-based drug design: from nucleic acid to membrane protein targets.

Authors:  Magdalena M Dailey; Chayanendu Hait; Patrick A Holt; Jon M Maguire; Jason B Meier; M Clarke Miller; Luigi Petraccone; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.